Daewoong Pharmaceutical Co.,Ltd sell "FEXUCLUE®"

FEXUCLUE (fexuprazan) is a novel acid-suppressing agent positioned as best-in-class for its fast onset and potent efficacy, addressing gaps left by conventional PPIs. It launched in Korea in 2022 and the Philippines in 2023, has been approved in Chile and Ecuador, has NDAs under review in China, Brazil, Mexico, Colombia, Peru, Thailand, and Saudi Arabia, among others, and additional dosages and indications remain in development.